ABSTRACT
BACKGROUND: A functional variant in the MDM2 promoter (a T/G substitution, SNP309) was found to be associated with increased expression of MDM2 gene products and at significantly earlier age onset of tumors in both hereditary Li-Fraumeni individuals and sporadic cancer patients. We tested the hypothesis that this functional variant was associated with either risk or early age diagnosis of cervical cancer in a Brazilian population. METHODS: A primer-introduced restriction analysis PCR assay was used to genotype the MDM2 SNP309 of 72 cervical carcinoma patients and 100 healthy women. RESULTS: No statistically significant association was observed between SNP309 and cervical cancer. We did not find allele or genotype frequency differences between the group of patients with cancer diagnosis at an early age (younger than 40 years old) and the group of older patients. CONCLUSIONS: Our findings suggest that SNP309 MDM2 may not be a risk factor for cervical cancer.
Subject(s)
Carcinoma/genetics , Polymorphism, Single Nucleotide , Promoter Regions, Genetic/genetics , Proto-Oncogene Proteins c-mdm2/genetics , Uterine Cervical Neoplasms/genetics , Adult , Age of Onset , Brazil , Female , Humans , Immunoblotting , Middle Aged , Papillomavirus Infections/epidemiology , Polymerase Chain ReactionABSTRACT
Polimorfismos do gene da proteína supressora de tumor p53 (TP53) têm sido estudados como possíveis fatores de risco para o desenvolvimento de diferentes tipos de câncer. O objetivo deste estudo foi verificar se o polimorfismo de comprimento de fragmento de restrição para MspI no íntron 6 do TP53 (nucleotídeo 13494) poderia influenciar no desenvolvimento do câncer do colo do útero na população do Rio Grande do Norte. Os resultados obtidos sugerem que o alelo A1 do MspI (ausência do sítio de restrição)não está associado a uma maior susceptibilidade ao câncer do colo do útero na população estudada.
